{"brief_title": "A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)", "brief_summary": "The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.", "detailed_description": "The primary objective of this study is to determine the activity of OSI-461 given twice daily orally in previously untreated CLL patients. The secondary objective is to evaluate the safety profile of OSI-461 in this patient population.", "condition": ["Chronic Lymphocytic Leukemia"], "intervention_type": ["Drug"], "intervention_name": ["OSI-461"], "criteria": "Inclusion Criteria: - Diagnosis of CLL established by bone marrow aspiration and biopsy or flow cytometry of peripheral blood. - No previous therapy for CLL. - Expected remaining life span greater than or equal to six months. - 18 years or older. - Willingness and ability to sign an informed consent. Exclusion Criteria: - Other active malignancy or history of treatment of any malignancy (excluding non-melanoma skin cancer) within the previous three years. - History of other malignancy which could affect the diagnosis or assessment of OSI-461. - Previous therapy for CLL. - Use of an investigational medication or device within one month of initiating study therapy. - Concurrent immunotherapy. - Use of steroids at the time of enrollment (patients who require steroids after enrollment may remain on study). - Any condition or any medication which may interfere with the conduct of the study. - Serious uncontrolled intercurrent medical or psychiatric illness, including serious infection. - Evidence of CNS involvement. - Pregnant or nursing women.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "CLL", "mesh_term": ["Leukemia", "Leukemia, Lymphoid", "Leukemia, Lymphocytic, Chronic, B-Cell"], "id": "NCT00073489"}